MorphoSys AG (FSE: MOR; Prime Standard Segment; TecDAX) intends to place 652,188 new shares through an accelerated book building process to institutional investors in Europe and North America. The Management and Supervisory Boards of MorphoSys AG decided to increase the Company's equity capital against contribution in cash, excluding preemptive rights. Société Générale and WestLB AG will act as joint lead managers for this transaction, and are joined by Janney Montgomery Scott acting as selling agent in the USA.
MorphoSys intends to use the issue proceeds to further expand the Company's business activities mainly in the research antibody segment, operating under the brand AbD Serotec, and accelerate further growth of the Group.